Outlook on the Biopsy Global Market to 2027 – Industry Trends, Growth, Impact of Inflation and Opportunities – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “China Biopsy Market, Volume, Size, Forecast 2023-2027” report has been added to ResearchAndMarkets.com’s offering.

This report provides a detailed analysis of China Biopsy Industry. The China Biopsy Market is expected to reach US$ 7.54 Billion by 2027.

Companies Mentioned

• Becton, Dickinson and Company
• Thermo Fisher Scientific Inc
• Bio-Rad Laboratories
• Exact Sciences (Genomic Health)
• Biocept
• Biocartis
• Roche Diagnostics
• Myriad Genetics Inc.
• Qiagen
• NeoGenomics Laboratories
• Quest Diagnostics Inc.

Since 2000, the number of cancer cases and deaths and the crude incidence and mortality of cancer have continuously climbed in China. Long-term trends in cancer burden and rates reflect patterns in cancer-risk behaviors and changes in medical practice, such as the adoption of cancer screening tests.

Furthermore, China is attempting to address its fast-rising cancer burden. However, rising population aging and the cumulative impact of risk factor exposure mean that cancer prevention faces many new obstacles.

Trends in China Biopsy Industry Prevailing Currently:

China is transitioning to developed-country cancer profiles, including high breast cancer rates, prostate cancer, lung cancer, liver cancer, thyroid cancer, colon and rectum cancer, kidney cancer, leukemia cancer, pancreatic cancer, and bladder cancer. These developments fuel a push for mass cancer screening and early detection among the 45 to 74-year-old group. As a result, China Biopsy Market Size is expected to expand at a CAGR of 6.25% during 2021-2027.

Although imaging procedures such as X-rays and CT scans can help detect areas of concern, they cannot distinguish between malignant and noncancerous cells. Consequently, a biopsy is the only reliable approach to identifying most cancers for cancer diagnosis.

To lower the cancer burden in China, biopsy screening technologies and procedures have been developed. However, the most viable option in the near future may be to provide coordinated screening for high-risk locations and opportunistic screening for non-high-risk areas.

Key Topics Covered:

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

4.1 Growth Drivers

4.2 Challenges

5. Market & Volume Analysis – China Biopsy Test

5.1 Market

5.2 Volume

6. Market & Volume Share Analysis – China Biopsy Test

6.1 Market Share

6.2 Volume Share

7. Application Analysis – China Biopsy Test Market

7.1 Breast Cancer

7.1.1 Market

7.1.2 Volume (Biopsy)

7.1.3 Diagnosed

7.2 Prostate Cancer

7.2.1 Market

7.2.2 Volume (Biopsy)

7.2.3 Diagnosed

7.3 Lung Cancer

7.3.1 Market

7.3.2 Volume (Biopsy)

7.3.3 Diagnosed

7.4 Liver Cancer

7.4.1 Market

7.4.2 Volume (Biopsy)

7.4.3 Diagnosed

7.5 Thyroid Cancer

7.5.1 Market

7.5.2 Volume (Biopsy)

7.5.3 Diagnosed

7.6 Kidney Cancer

7.6.1 Market

7.6.2 Volume (Biopsy)

7.6.3 Diagnosed

7.7 Colon & Rectum Cancer

7.7.1 Market

7.7.2 Volume (Biopsy)

7.7.3 Diagnosed

7.8 Pancreas Cancer

7.8.1 Market

7.8.2 Volume (Biopsy)

7.8.3 Diagnosed

7.9 Leukaemia

7.9.1 Market

7.9.2 Volume (Biopsy)

7.9.3 Diagnosed

7.10 Bladder

7.10.1 Market

7.10.2 Volume (Biopsy)

7.10.3 Diagnosed

8. Merger & Acquisition

9. Company Analysis

For more information about this report visit https://www.researchandmarkets.com/r/d71993.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900